The clinical efficacy analysis of the entecavir antiviral therapy for patients with decompensated hepatitis B cirrhosis / 中国现代医生

ABSTRACT

Objective To seek more effective antiviral therapy for decompensated hepatitis B cirrhosis and improve the prognosis by observing the clinical efficacy of entecavir in treating decompensated hepatitis B cirrhosis. Methods All the outpatients and inpatients in department of infectious diseases of our hospital from April 2013 to March 2014 were chosen. According to the 2010 edition of Chronic hepatitis B prevention and treatment guidelines, 18 patients with de-compensated hepatitis B cirrhosis in line with initial indications of antiviral therapy were included. The patients re-ceived regularly follow-up every 3 months, and related examinations of biochemistry, virology and imaging were com-pleted. The evaluation indexes of patients during treatment were compared, the related data was analyzed by SPSS 13.0 software, and evaluated effects of drugs. Results The indicators including HBV-DNA, liver function and prothrombin activity of patients during treatment were compared, and the differences in comparing with indicators before and after treatment were statistically significant (P<0.05). Conclusion Entecavir in the treatment of decompensated hepatitis B cirrhosis is characterized by high antiviral ability, safety, and significant efficacy.